# Clinical Pharmacology Considerations for Peptide Drug Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8

> FDA guidance document: Clinical Pharmacology Considerations for Peptide Drug Products. Issue date: December 14, 2023. Get complete insights and analysis.

---

## Details

- Title: Clinical Pharmacology Considerations for Peptide Drug Products
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-12-14
- Comment Close Date: 2023-12-11
- Last Changed: 2023-12-13
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-3391">FDA-2023-D-3391</a>

## Related Documents

- [Psychedelic Drugs: Considerations for Clinical Investigations](https://www.globalkeysolutions.net/guidances/guidance-document/psychedelic-drugs-considerations-for-clinical-investigations/c22c8005-efa9-4373-893d-cf27911562b6)
- [Quality Considerations for Topical Ophthalmic Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/quality-considerations-for-topical-ophthalmic-drug-products/19494a43-f26e-42c9-b1ad-99a1126b3d42)
- [General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological-products/764daa65-55f6-4702-b131-6e18ebf48434)